Notizia - Recent Pharma, Healthcare and Biotech Happenings

EU recommends the use of Imbruvica for two new indications The Janssen Pharmaceutical has received the approval for its drug Imbruvica (ibrutinib) from the European Commission (EC). Ibrutinib is a first-in-class targeted therapy, which inhibits the function of Bruton's tyrosine kinase (BTK). Jointly developed and commercialized by Janssen Biotech, and Pharmacyclics LLC, an AbbVie, Imbruvica has been approved chronic lymphocytic leukaemia (CLL) and Waldenström's macroglobulinemia (WM). This includes the use of ibrutinib in combination with obinutuzumab in adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and the use of ibrutinib plus ritux...